HK1167402A1 - Phenoxymethyl heterocyclic compounds - Google Patents

Phenoxymethyl heterocyclic compounds

Info

Publication number
HK1167402A1
HK1167402A1 HK12108181.8A HK12108181A HK1167402A1 HK 1167402 A1 HK1167402 A1 HK 1167402A1 HK 12108181 A HK12108181 A HK 12108181A HK 1167402 A1 HK1167402 A1 HK 1167402A1
Authority
HK
Hong Kong
Prior art keywords
heterocyclic compounds
phenoxymethyl
phenoxymethyl heterocyclic
compounds
ylmethoxy
Prior art date
Application number
HK12108181.8A
Other languages
English (en)
Inventor
Gideon Shapiro
Amy Ripka
Richard Chesworth
Original Assignee
Envivo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Envivo Pharmaceuticals Inc filed Critical Envivo Pharmaceuticals Inc
Publication of HK1167402A1 publication Critical patent/HK1167402A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK12108181.8A 2009-05-07 2012-08-21 Phenoxymethyl heterocyclic compounds HK1167402A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17641309P 2009-05-07 2009-05-07
PCT/US2009/068644 WO2010128995A1 (en) 2009-05-07 2009-12-18 Phenoxymethyl heterocyclic compounds

Publications (1)

Publication Number Publication Date
HK1167402A1 true HK1167402A1 (en) 2012-11-30

Family

ID=41549054

Family Applications (2)

Application Number Title Priority Date Filing Date
HK12108181.8A HK1167402A1 (en) 2009-05-07 2012-08-21 Phenoxymethyl heterocyclic compounds
HK14100085.0A HK1186981A1 (en) 2009-05-07 2014-01-06 Phenoxymethyl heterocyclic compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK14100085.0A HK1186981A1 (en) 2009-05-07 2014-01-06 Phenoxymethyl heterocyclic compounds

Country Status (33)

Country Link
US (3) US8343973B2 (ru)
EP (3) EP2617420B1 (ru)
JP (2) JP5628902B2 (ru)
KR (1) KR101662699B1 (ru)
CN (2) CN102459242B (ru)
AU (1) AU2009345802B2 (ru)
BR (1) BRPI0924617A8 (ru)
CA (1) CA2761032A1 (ru)
CL (1) CL2011002792A1 (ru)
CO (1) CO6460744A2 (ru)
CR (1) CR20110648A (ru)
DK (2) DK2427454T3 (ru)
EC (1) ECSP11011479A (ru)
ES (2) ES2554788T3 (ru)
HK (2) HK1167402A1 (ru)
HR (2) HRP20130482T1 (ru)
HU (1) HUE026238T2 (ru)
IL (2) IL216149A (ru)
ME (1) ME02375B (ru)
MX (1) MX2011011755A (ru)
MY (1) MY183910A (ru)
NZ (1) NZ596753A (ru)
PE (1) PE20120900A1 (ru)
PH (1) PH12013501321B1 (ru)
PL (2) PL2427454T3 (ru)
PT (2) PT2427454E (ru)
RS (2) RS54529B1 (ru)
RU (1) RU2531274C2 (ru)
SG (1) SG175900A1 (ru)
SI (2) SI2617420T1 (ru)
SM (2) SMT201300070B (ru)
WO (1) WO2010128995A1 (ru)
ZA (1) ZA201108920B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2297133B1 (en) 2008-06-25 2017-09-13 Forum Pharmaceuticals Inc. 1, 2 disubstituted heterocyclic compounds
PT2427454E (pt) 2009-05-07 2013-06-20 Envivo Pharmaceuticals Inc Compostos fenoximetilo heterocíclicos
JP2014510055A (ja) 2011-02-18 2014-04-24 アラーガン インコーポレイテッド ホスホジエステラーゼ１０（ｐｄｅ１０ａ）阻害剤としての置換６，７−ジアルコキシ−３−イソキノリノール誘導体
AU2012382373A1 (en) 2012-06-12 2014-12-11 Abbvie Inc. Pyridinone and pyridazinone derivatives
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
ES2480341B1 (es) 2013-01-24 2015-01-22 Palobiofarma S.L Nuevos derivados de pirimidina como inhibidores de la fosfodiesterasa 10 (PDE-10)
TW201512201A (zh) * 2013-03-14 2015-04-01 Forum Pharmaceuticals Inc 化合物的多晶型及鹽類
TWI634114B (zh) * 2013-05-08 2018-09-01 永恒生物科技公司 作為激酶抑制劑之呋喃酮化合物
US10039764B2 (en) 2013-07-12 2018-08-07 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ518420A (en) * 1999-11-05 2004-02-27 Sod Conseils Rech Applic Heterocyclic compounds having an inhibitory activity on calpains or a trapping activity on reactive oxygen species (ROS's) and their use as medicines
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
AU2003244080A1 (en) 2002-06-26 2004-01-19 Kyowa Hakko Kogyo Co., Ltd. Phosphodiesterase inhibitor
EP1841757B1 (en) * 2005-01-07 2010-06-30 Pfizer Products Incorporated Heteroaromatic quinoline compounds and their use as pde10 inhibitors
NL2000397C2 (nl) * 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
EP1845098A1 (en) * 2006-03-29 2007-10-17 Ferrer Internacional, S.A. Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands
US20090176829A1 (en) * 2006-05-02 2009-07-09 Pfizer Inc Bicyclic heteroaryl compounds as pde10 inhibitors
WO2008033455A2 (en) 2006-09-13 2008-03-20 The Institutes For Pharmaceutical Discovery, Llc Biphenyl and heteroaryl phenyl derivatives as protein tyrosine phosphatases inhibitors
FR2928924B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique
EP2297133B1 (en) * 2008-06-25 2017-09-13 Forum Pharmaceuticals Inc. 1, 2 disubstituted heterocyclic compounds
PT2427454E (pt) 2009-05-07 2013-06-20 Envivo Pharmaceuticals Inc Compostos fenoximetilo heterocíclicos
WO2011028995A1 (en) * 2009-09-03 2011-03-10 Allergan, Inc. Compounds as tyrosine kinase modulators
DK3311666T3 (da) * 2010-08-18 2021-06-28 Biosplice Therapeutics Inc Diketoner og hydroxyketoner som aktivatorer af catenin-signalvejen

Also Published As

Publication number Publication date
RU2531274C2 (ru) 2014-10-20
PL2617420T3 (pl) 2016-04-29
HRP20130482T1 (en) 2013-08-31
NZ596753A (en) 2013-09-27
US20150322069A1 (en) 2015-11-12
ES2409404T3 (es) 2013-06-26
JP2015038112A (ja) 2015-02-26
CL2011002792A1 (es) 2012-06-01
RU2011149637A (ru) 2013-06-20
CN105125547A (zh) 2015-12-09
PT2617420E (pt) 2015-12-18
EP2617420A1 (en) 2013-07-24
JP2012526107A (ja) 2012-10-25
EP2427454B1 (en) 2013-03-20
IL216149A (en) 2016-02-29
CR20110648A (es) 2012-03-28
KR101662699B1 (ko) 2016-10-05
HUE026238T2 (en) 2016-06-28
KR20120027268A (ko) 2012-03-21
CA2761032A1 (en) 2010-11-11
RS52838B (en) 2013-10-31
CO6460744A2 (es) 2012-06-15
WO2010128995A1 (en) 2010-11-11
DK2427454T3 (da) 2013-06-17
ME02375B (me) 2016-06-20
US8946222B2 (en) 2015-02-03
CN102459242A (zh) 2012-05-16
ECSP11011479A (es) 2011-12-30
PL2427454T3 (pl) 2013-09-30
SMT201300070B (it) 2013-09-06
SMT201600031B (it) 2016-02-25
RS54529B1 (en) 2016-06-30
EP2427454A1 (en) 2012-03-14
MX2011011755A (es) 2012-03-16
AU2009345802B2 (en) 2016-05-26
PH12013501321A1 (en) 2014-08-27
US20100292238A1 (en) 2010-11-18
IL216149A0 (en) 2012-01-31
AU2009345802A1 (en) 2011-12-15
BRPI0924617A2 (ru) 2017-07-11
SI2617420T1 (sl) 2016-02-29
JP5628902B2 (ja) 2014-11-19
PH12013501321B1 (en) 2014-08-27
BRPI0924617A8 (pt) 2017-10-03
EP3020716A1 (en) 2016-05-18
EP2617420B1 (en) 2015-09-23
JP5943053B2 (ja) 2016-06-29
ZA201108920B (en) 2012-08-29
HRP20151273T1 (hr) 2016-01-29
PE20120900A1 (es) 2012-08-14
IL244059A0 (en) 2016-04-21
CN102459242B (zh) 2015-08-26
DK2617420T3 (da) 2015-12-07
ES2554788T3 (es) 2015-12-23
PT2427454E (pt) 2013-06-20
SG175900A1 (en) 2011-12-29
MY183910A (en) 2021-03-17
US8343973B2 (en) 2013-01-01
HK1186981A1 (en) 2014-03-28
US20130143888A1 (en) 2013-06-06
SI2427454T1 (sl) 2013-08-30

Similar Documents

Publication Publication Date Title
HK1167402A1 (en) Phenoxymethyl heterocyclic compounds
AU2013277298B2 (en) Substituted pyridine azolopyrimidine - 5 - (6h) - one compounds
NZ599334A (en) Synthetic methods for spiro-oxindole compounds
HRP20160096T1 (hr) Supstituirani derivati izokinolina
NZ630721A (en) Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use
MX2013005535A (es) Compuesto de 3- (amino-aril) -piridina.
MX2010009458A (es) Derivados biciclicos heterociclicos o espirobiciclicos heterociclicos enlazados, de pirazolo[1,5-a]pirimidinas, procedimientos para su preparacion y usos de los mismos.
TN2013000285A1 (en) Novel heterocyclic derivatives and their use in the treatment of neurological disorders
WO2009091374A3 (en) Fused heterocyclic derivatives and methods of use as c-met inhibitors
MY183373A (en) Pyridine and pyrazine derivatives as protein kinase modulators
NZ591166A (en) Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
SG179034A1 (en) 2 -aminodihydro [1, 3] thiazines as bace 2 inhibitors for the treatment of diabetes
PE20090506A1 (es) DERIVADOS DE IMIDAZO-[1,2-b]-PIRIDAZIN COMO INHIBIDORES DE ALK5 Y/O ALK4
WO2014164767A1 (en) Novel compounds and compositions for inhibition of fasn
MX2010008469A (es) Pirazolopirimidinas, procedimiento para su preparacion y su uso como medicina.
TW201000488A (en) Heterocyclic derivatives
ATE478876T1 (de) Thienopyridine als allosterische verstärker des m4-muscarinrezeptors
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
NO20091590L (no) Heterocykliske amidforbindelser anvendbare som kinaseinhibitorer
RU2013135477A (ru) Гетероциклические соединения и их применение в качестве ингибиторов киназы-3 гликогенсинтазы
MX2010009922A (es) Activadores de piridazinona glucocinasa.
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten
GEP20166483B (en) Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament
EA201490630A1 (ru) 6-замещенные 3-(хинолин-6-илтио)[1,2,4]триазоло[4,3-a]пиридины в качестве ингибиторов c-met тирозинкиназы
EP2602255A4 (en) FUSED HETEROCYCLIC CYCLE COMPOUND

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20161218